NextPlat (NXPL) Capital Expenditures Growth (1y) (2016 - 2026)
Powered by 
Analysis
NextPlat (NXPL) Capital Expenditures Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 8.33% |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | -0.19% |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 54.86% |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 34.46% |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | -22.22% |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | -23.92% |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | - |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | -18.68% |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | -15.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.87% |
| Mar 31, 2026 | -82.76% |
| Dec 31, 2025 | 215.63% |
| Jun 30, 2025 | 5.00% |
| Mar 31, 2025 | -145.31% |
| Dec 31, 2024 | -116.93% |
| Sep 30, 2024 | -72.68% |
| Jun 30, 2024 | 76.47% |
| Mar 31, 2024 | -7.25% |
| Dec 31, 2023 | -22.82% |
| Sep 30, 2023 | 367.89% |
| Jun 30, 2023 | -89.61% |
| Mar 31, 2023 | 1.48% |
| Dec 31, 2022 | 83.15% |
| Sep 30, 2022 | 11.01% |
| Jun 30, 2022 | 1,121.58% |
| Mar 31, 2022 | 14,714.16% |
| Dec 31, 2021 | 3,121.13% |
| Sep 30, 2021 | 1,388.13% |
| Jun 30, 2021 | 75.94% |